Influenza Diagnostics Market Expected to Reach USD 2,711.50 Million by 2032 | Persistence Market Research

The global influenza diagnostics market is witnessing significant growth, driven by the rising prevalence of influenza and the increasing adoption of advanced diagnostic technologies. As of 2025, the market size is valued at US$ 1,803.30 Mn and is projected to reach US$ 2,711.50 Mn by 2032, expanding at a CAGR of 6.00% during the forecast period. Molecular diagnostic assays, particularly RT-PCR and nucleic acid detection techniques, have become the gold standard for influenza detection due to their high specificity and sensitivity.

Among the various market segments, rapid influenza diagnostic tests (RIDTs) hold a dominant position due to their quick results and ease of use. Geographically, North America leads the market, with the U.S. accounting for a substantial share due to high flu prevalence, government support, and the presence of key industry players like Abbott and Quidel Corporation.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/13246

Key Highlights from the Report

The market is expected to grow at a CAGR of 6.00% from 2025 to 2032.

The RT-PCR segment is gaining traction due to its accuracy in detecting influenza viruses.

North America dominates the market, with the U.S. leading due to advanced healthcare infrastructure.

Rising influenza cases worldwide are driving the demand for faster and more efficient diagnostic solutions.

The hospital segment holds a significant market share due to increased patient inflow for diagnostic tests.

Recent mergers and acquisitions are shaping the competitive landscape, enhancing innovation in diagnostic technologies.

Market Segmentation

The influenza diagnostics market is segmented based on product type, end-user, and diagnostic method.

Product Type:

Molecular diagnostic tests, such as RT-PCR and nucleic acid amplification tests (NAATs), hold a significant market share due to their ability to provide precise results. Traditional rapid antigen tests continue to be widely used in primary healthcare settings due to their cost-effectiveness and quick turnaround time.

End-User:

Hospitals dominate the market, accounting for approximately 53.9% of the total market share in 2024. The increasing number of diagnostic laboratories and point-of-care (POC) testing facilities has also contributed to market expansion. Home-based testing is emerging as a new trend, driven by technological advancements and the need for faster self-diagnosis options.

Regional Insights

North America:

The United States accounts for nearly 89.6% of the North American market, driven by high influenza incidence rates, increased funding for diagnostic research, and strong healthcare infrastructure. The presence of leading diagnostic companies further propels market growth.

Europe:

Germany leads the European market, contributing 35.3% of the global market share in 2024. The country's commitment to research and innovation in rapid diagnostic test development makes it a lucrative region for market expansion.

Asia-Pacific:

The Asia-Pacific region is witnessing rapid growth due to increasing government initiatives for infectious disease control, rising healthcare investments, and growing awareness about early diagnosis.

Market Drivers, Restraints, and Opportunities

Market Drivers:

Increasing prevalence of influenza worldwide, leading to a surge in diagnostic demand.

Advancements in molecular diagnostic technologies, particularly RT-PCR and NAATs.

Government and private sector investments in influenza research and diagnostics.

Market Restraints:

High costs of molecular diagnostic tests, limiting accessibility in developing regions.

Shortage of skilled laboratory professionals required for complex diagnostic procedures.

False positive and false negative results in rapid diagnostic tests, affecting reliability.

Market Opportunities:

Emergence of home-based influenza diagnostic kits, catering to growing consumer demand for convenience.

Expansion into emerging markets, particularly in Asia-Pacific, where healthcare investments are rising.

Integration of AI and machine learning in diagnostic tools, enhancing test accuracy and efficiency.

Frequently Asked Questions (FAQs)

->How big is the influenza diagnostics market?

The influenza diagnostics market was valued at US$ 1,803.30 Mn in 2025 and is expected to reach US$ 2,711.50 Mn by 2032.

->Who are the key players in the global influenza diagnostics market?

Leading companies include Abbott Laboratories, F. Hoffmann-La Roche Ltd, Quidel Corporation, Hologic, Inc., BD (Becton, Dickinson and Company), Thermo Fisher Scientific Inc., and Danaher Corporation.

->What is the projected growth rate of the influenza diagnostics market?

The market is anticipated to grow at a CAGR of 6.00% from 2025 to 2032.

->Which region is estimated to dominate the industry through the forecast period?

North America, particularly the United States, is expected to maintain dominance due to high influenza prevalence, advanced healthcare infrastructure, and strong presence of key market players.

Company Insights

Key players operating in the influenza diagnostics market include:

Abbott Laboratories

F. Hoffmann-La Roche Ltd

Quidel Corporation

Hologic, Inc.

BD (Becton, Dickinson and Company)

Thermo Fisher Scientific Inc.

Danaher Corporation

Recent Developments:

In March 2021, Roche acquired GenMark Diagnostics, Inc. for US$ 1.8 billion, expanding its molecular diagnostics portfolio.

In October 2020, Quidel Corporation received USFDA approval for its SARS Antigen FIA + Sofia 2 Flu test, enhancing its product line for influenza diagnostics.

The influenza diagnostics market is poised for substantial growth in the coming years, fueled by advancements in diagnostic technologies, increasing flu cases, and the need for rapid and accurate testing. Stakeholders should focus on technological innovation, expansion into emerging markets, and strategic collaborations to maintain a competitive edge.

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.